CNIO researchers Bruna Calsina and Mercedes Robledo. Credit: Laura M. Lombardía, CNIO
Mercedes Robledo, head of the Hereditary Endocrine Cancer Group at the Spanish National Cancer Research Center and one of the two researchers who led the study, has been studying these tumors since 1996. He says,"One of the difficulties of working with that our study gathers corresponds to a population of 100 million people." This has been possible thanks to the collaboration between 16 centers from six countries around the world, with which the CNIO has been collaborating for the last decade.
As Robledo and Calsina explain, most patients with this type of tumor who develop metastasis do so one or two years after the diagnosis of the disease, but there are cases in which metastasis develops ten or twenty years after the initial diagnosis. The new molecular markers will help clinicians to follow more closely those patients at high risk of metastasis.Another problem with this rare disease is that the therapies do not always work, and the reason is unknown.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: medical_xpress - 🏆 101. / 51 Read more »